Thornes Pharma Holdings Limited Filleted accounts for Companies House (small and micro)

COMPANY REGISTRATION NUMBER: 11643777

Thornes Pharma Holdings Limited

Filleted Unaudited Financial Statements

For the year ended

30 November 2025

Thornes Pharma Holdings Limited

Financial Statements

Year ended 30 November 2025

Contents	Page

Officers and professional advisers	1

Accountant's report to the board of directors on the preparation of the unaudited statutory financial statements of Thornes Pharma Holdings Limited	2

Statement of financial position	3

Notes to the financial statements	5

Thornes Pharma Holdings Limited

Officers and Professional Advisers

The board of directors	Mr N J Thorne
	Mr D W Fairclough
	Mrs J Thorne
	Mrs E M Fairclough

Registered office	2 Oldfield Road
	Bocam Park
	Bridgend
	United Kingdom
	CF35 5LJ

Accountants	Clay Shaw Thomas Ltd

	2 Oldfield Road
	Bocam Park
	Bridgend
	CF35 5LJ

Thornes Pharma Holdings Limited

Accountant's Report to the Board of Directors on the Preparation of the Unaudited Statutory Financial Statements of Thornes Pharma Holdings Limited

Year ended 30 November 2025

As described on the statement of financial position, the directors of the company are responsible for the preparation of the financial statements for the year ended 30 November 2025, which comprise the statement of financial position and the related notes. You consider that the company is exempt from an audit under the Companies Act 2006. In accordance with your instructions we have compiled these financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and from information and explanations supplied to us.

Clay Shaw Thomas Ltd

2 Oldfield Road Bocam Park Bridgend CF35 5LJ

5 May 2026

Thornes Pharma Holdings Limited

Statement of Financial Position

30 November 2025

	2025		2024
Note	£	£	£

Fixed assets

Investments	4		1,950,000	1,950,000

Current assets

Debtors	5	13,000	3,000
Cash at bank and in hand		300	300
		--------	-------
		13,300	3,300

Creditors: amounts falling due within one year	6	11,503		10,127
		--------		--------
Net current assets/(liabilities)			1,797	( 6,827)
			------------	------------
Total assets less current liabilities			1,951,797	1,943,173
			------------	------------
Net assets			1,951,797	1,943,173
			------------	------------

Capital and reserves

Called up share capital	104	104
Other reserves	1,950,000	1,950,000
Profit and loss account	1,693	( 6,931)
	------------	------------
Shareholders funds	1,951,797	1,943,173
	------------	------------

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.

For the year ending 30 November 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;

- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .

Thornes Pharma Holdings Limited

Statement of Financial Position (continued)

30 November 2025

These financial statements were approved by the board of directors and authorised for issue on 5 May 2026 , and are signed on behalf of the board by:

Mr N J Thorne

Director

Company registration number: 11643777

Thornes Pharma Holdings Limited

Notes to the Financial Statements

Year ended 30 November 2025

1. General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 2 Oldfield Road, Bocam Park, Bridgend, CF35 5LJ, United Kingdom.

2. Statement of compliance

These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Going concern

The directors have assessed whether there are any material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue. In assessing whether the going concern assumption is appropriate, the directors have taken in to account all available information about the future, and conclude that the company has adequate resources to to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis in preparing its financial statements.

Consolidation

The company has taken advantage of the option not to prepare consolidated financial statements contained in Section 398 of the Companies Act 2006 on the basis that the company and its subsidiary undertakings comprise a small group.

Investments

Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.

Impairment of fixed assets

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets.

4. Investments

	Shares in group
	£
Cost
At 1 December 2024 and 30 November 2025	1,950,000
	------------
Impairment
At 1 December 2024 and 30 November 2025	–
	------------

Carrying amount
At 30 November 2025	1,950,000
	------------
At 30 November 2024	1,950,000
	------------

5. Debtors

	2025	2024
	£	£
Other debtors	13,000	3,000
	--------	-------

6. Creditors: amounts falling due within one year

	2025	2024
	£	£
Amounts owed to group undertakings	8,098	8,059
Other creditors	3,405	2,068
	--------	--------
	11,503	10,127
	--------	--------

7. Related party transactions

Thornes Pharmacy Limited is a 100% subsidiary of Thornes Pharma Holdings Limited and as such has taken advantage of the exemption stated in FRS 102 whereby disclosure need not be given of transactions entered into between two or more members of the same group, provided that any subsidiary which is party to the transaction is wholly owned by such member. The company has also taken exemption under the small companies regime from disclosing related party transactions that are either considered immaterial or concluded under normal market conditions.